Anti-Mouse CD90 (Thy-1) (Clone HK2.1) – Purified in vivo GOLD™ Functional Grade

Pricing & Details

Product No.C335
Clone
HK2.1
Protein
CD90
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Thy-1, CD90, CDw90
Isotype
Rat
IgG2c
Applications
FA
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
C335-1.0 mg
1.0 mg
$105.00
In stock
Max:
Min: 1
Step: 1
C335-5.0 mg
5.0 mg
$355.00
In stock
Max:
Min: 1
Step: 1
C335-25 mg
25 mg
$965.00
In stock
Max:
Min: 1
Step: 1
C335-50 mg
50 mg
$1,595.00
In stock
Max:
Min: 1
Step: 1
C335-100 mg
100 mg
$2,300.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone HK2.1 recognizes a non-polymorphic determinant on mouse CD90 (Thy1.1 and Thy1.2 alloantigens).
Antigen Distribution
CD90 is expressed by thymocytes, peripheral T cells, myoblasts, epidermal cells, and keratinocytes.
Background
CD90 is a 28-30 kD GPI-linked membrane glycoprotein and is part of the Ig superfamily. It interacts with CD45 in signal transduction. CD90 mediates adhesion of thymocytes to thymic stroma. It has been reported that CD90 binds with β2 and β3 integrins and is involved in the inhibition of hematopoietic stem cells proliferation and differentiation, as well as the regulation of cell adhesion and neurite outgrowth. It can be used as a marker for various stem cells, such as hematopoietic stem cells, and for the axonal processes of mature neurons. For use in FACS, CD90 is a popular surface marker for stem cells in combination with other markers such as CD34. There are two alleles for CD90 in mice that differ by one amino acid. The difference being that CD90.1 (Thy1.1) has an arginine and CD90.2 (Thy1.2) has a glutamine at position 108. CD90.2 is more prevalent and is expressed in most mice strains. CD90.1 is only expressed by a select few mice strains including AKR/J and PL strains. CD90.2 is a 25-35 kD GPI-anchored membrane glycoprotein. Like CD90, it is also in the Ig superfamily, interacts with CD45, and has involvement in signal transduction. The function of CD90.2 is thought to play roles in cognition, axon growth, T lymphocyte function, and apoptosis. CD90 acts as tumor suppressor for some tumors due to its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. On the other hand, it has been suspected to aid in the spread of circulating melanoma cells. Regarding prostate cancer, CD90 has therapeutic potential for specific drug targeting due to its expression in cancer associated stroma, but not in normal stroma.

Antigen Details

Protein
Ligand/Receptor
CD45
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Stem Cell

References & Citations

1. Ledbetter, J. A. et al. (1979) Immunol. Rev. 47:63 2. Ledbetter, J. A. et al. (1980) J. Exp. Med. 152:280 3. Lancki, D. W. et al. (1984) Immunol. Rev. 81:65
General Western Blot Protocol

Formats Available